drugset / Trial / NCT02992652
Allopurinol in Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
RandomizedParallel-groupOpen-labelPrevention
Summary
* The investigators evaluated the role of allopurinol in prevention of post-ERCP pancreatitis. * 100 Egyptian patients who were candidates for ERCP were included and divided into two groups. Group 1 (study group) included 50 patients who received two doses of allopurinol 300 mg each, 15 hours and 3 hours before ERCP and Group 2 (control group) included 50 patients who did not receive allopurinol prophylaxis.
Timeline
- Start
- 2011-01
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Allopurinol | Small molecule | 300 mg | Oral |
Indications
No indication recorded.